Pharsight

Drugs that contain Vasopressin

1. Vasostrict patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375478 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9744209 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9937223 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9744239 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US10010575 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9981006 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9974827 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9968649 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9962422 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9925234 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9925233 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9687526 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9750785 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9919026 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

Market Authorisation Date: 17 April, 2014

Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of VASOSTRICT before it's drug patent expiration?
More Information on Dosage

VASOSTRICT family patents

Family Patents